Health Insurance Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Caritas St. Elizabeth's Medical Center, Brighton

Researchers from the United States and Republic of China publish new studies and findings in the area of cancer treatment

Study 1: Chemotherapy-induced nausea and vomiting in women may be prevented by the addition of aprepitant.

According to researchers in the United States, "Prevention of chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics has been more difficult to achieve in female patients."

P.J. Hesketh and colleagues, Caritas St. Elizabeth's Medical Center in Brighton wrote, "Data from two phase III trials of the NK1 antagonist aprepitant were assessed for potential effect of gender on treatment response. 1,044 patients...

• View Other Issues of Health Insurance Law Weekly
  
• View Other NewsRx Publications